Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sherene Loi

Showing results (1-10 of 325) with videos related to

Pageof 33
Sort By:
Nature Medicine|October 9, 2019
Around the world and back againSherene Loi
Oncoimmunology|September 28, 2013
Tumor-infiltrating lymphocytes, breast cancer subtypes and therapeutic efficacySherene Loi
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 30, 2014
Host antitumor immunity plays a role in the survival of patients with newly diagnosed triple-negative breast cancerSherene Loi
The Lancet. Oncology|November 11, 2018
Fine-tuning chemotherapy in the era of dual HER2 targetingSherene Loi
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 11, 2015
Reply to A. Ocaña et al and P.G. Tsoutsou et alSherene Loi
Oncology (Williston Park, N.Y.)|May 17, 2015
Immune targeting in breast cancer: in whom and with what?Sherene Loi
European Journal of Cancer (Oxford, England : 1990)|November 8, 2008
Molecular analysis of hormone receptor positive (luminal) breast cancers: what have we learnt?Sherene Loi
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 13, 2016
Looking Deep Into the Heterogeneity of Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Can We Understand It Better?Sherene Loi, Peter Savas
Cancer Cell|May 13, 2020
Expanding the Role for Immunotherapy in Triple-Negative Breast CancerPeter Savas, Sherene Loi
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 4, 2019
Metastatic Breast Cancer: TIL it is Too LatePeter Savas, Sherene Loi
Pageof 33

Showing results (1-10 of 325) with videos related to

Sort By:
Pageof 33
Nature Medicine|October 9, 2019
Around the world and back againSherene Loi
Oncoimmunology|September 28, 2013
Tumor-infiltrating lymphocytes, breast cancer subtypes and therapeutic efficacySherene Loi
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 30, 2014
Host antitumor immunity plays a role in the survival of patients with newly diagnosed triple-negative breast cancerSherene Loi
The Lancet. Oncology|November 11, 2018
Fine-tuning chemotherapy in the era of dual HER2 targetingSherene Loi
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 11, 2015
Reply to A. Ocaña et al and P.G. Tsoutsou et alSherene Loi
Oncology (Williston Park, N.Y.)|May 17, 2015
Immune targeting in breast cancer: in whom and with what?Sherene Loi
European Journal of Cancer (Oxford, England : 1990)|November 8, 2008
Molecular analysis of hormone receptor positive (luminal) breast cancers: what have we learnt?Sherene Loi
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 13, 2016
Looking Deep Into the Heterogeneity of Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Can We Understand It Better?Sherene Loi, Peter Savas
Cancer Cell|May 13, 2020
Expanding the Role for Immunotherapy in Triple-Negative Breast CancerPeter Savas, Sherene Loi
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 4, 2019
Metastatic Breast Cancer: TIL it is Too LatePeter Savas, Sherene Loi
Pageof 33